NCT03027557 · OUTCOME

Vertebral Fracture Assessment - Final Scan

Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. · Source last updated 2021-05-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Number of participants with vertebral fractures as assessed by VFA at final scan.

Analysis population: One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.

15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.

16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.

15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Combined Treatment.	1	Not reported	Not reported	Not reported	Not reported
Denosumab Monotherapy	3	Not reported	Not reported	Not reported	Not reported
Placebo	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of participants with vertebral fractures as assessed by VFA at final scan.

groups

param Type

COUNT_OF_PARTICIPANTS

population Description

One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.

reporting Status

POSTED

time Frame

Patients with vertebral fractures at one year reported.

title

Vertebral Fracture Assessment - Final Scan

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice